Alphamab Oncology (09966.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

53.9x

Market Cap

HKD 8.43B

MomentumView details →

1D Return

−1.02%

YTD Return

−10.51%

RSI (14)

57.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

53.9x

Market Cap

HKD 8.43B

RSI (14)

57.0

MomentumView details →

1D Return

−1.02%

YTD Return

−10.51%

ProfitabilityView details →

Gross Margin

85.87%

Net Margin

4.54%

EBITDA Margin

8.65%

ROE (TTM)

3.53%

ROA (TTM)

2.73%

Asset Turnover

0.61x

GrowthView details →

Revenue YoY

+157.15%

EPS YoY

+114.75%

FCF YoY

+69.84%

Revenue CAGR 3Y

+48.97%

EPS CAGR 3Y

—

EBITDA YoY

+122.10%

EarningsView details →

EPS (Actual)

−HKD 0.05

EPS Surprise

89.36%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.32

Avg Surprise (4Q)

89.36%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

4.02x

Quick Ratio

3.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.30B

Net Income (TTM)

59.05M

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.5d ago

Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.8d ago

Similar companies

ImmunityBio, Inc.IBRX TG Therapeutics, Inc.TGTX CStone Pharmaceuticals02616.HK ST诺泰688076.SH Immunovant, Inc.IMVT Tennor Therap-b06872.HK Find similar companies →

Latest newsMore news →

Alphamab Oncology announced a resolution to repurchase its own shares from the open market, with a maximum amount of 80 million HKD.5d ago Alphamab Oncology (09966.HK) reported an interim net loss of 40.46 million RMB for the six months ended June 2026, compared with a net profit of 21.58 million RMB in the same period last year, with revenue down 15.1% year-on-year to 271 million RMB.8d ago